Difference between revisions of "Estramustine (Emcyt)"
Warner-admin (talk | contribs) m (Text replacement - " " to " ") |
Warner-admin (talk | contribs) m (Text replacement - "chemocare.com/chemotherapy/drug-info" to "chemocare.com/druginfo") |
||
| (One intermediate revision by one other user not shown) | |||
| Line 11: | Line 11: | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://www.pfizer.com/files/products/uspi_emcyt.pdf Estramustine (Emcyt) package insert]<ref name="insert"></ref> | *[http://www.pfizer.com/files/products/uspi_emcyt.pdf Estramustine (Emcyt) package insert]<ref name="insert"></ref> | ||
| − | *[https://chemocare.com/ | + | *[https://chemocare.com/druginfo/estramustine.aspx Estramustine (Emcyt) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/estramustine.aspx Estramustine (Emcyt) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/estramustine-patient-drug-information Estramustine (Emcyt) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/estramustine-patient-drug-information Estramustine (Emcyt) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/estramustine-patient-drug-information Estramustine (Emcyt) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/estramustine-patient-drug-information Estramustine (Emcyt) patient drug information (UpToDate)]</ref> | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*1981-12-24: Initial FDA approval | *1981-12-24: Initial FDA approval | ||
| − | + | ==History of changes in EMA indication== | |
| + | *1971-09-02: EURD | ||
==Also known as== | ==Also known as== | ||
*'''Generic name:''' estramustine phosphate sodium | *'''Generic name:''' estramustine phosphate sodium | ||
| Line 33: | Line 34: | ||
[[Category:FDA approved in 1981]] | [[Category:FDA approved in 1981]] | ||
| + | [[Category:EMA approved in 1971]] | ||
Revision as of 23:30, 2 September 2023
General information
Class/mechanism: Nornitrogen mustard (similar to mechlorethamine) linked to estradiol. The estradiol component helps the drug to be preferentially delivered to estrogen receptor-positive cells. The mustard component serves as an alkylator and causes DNA crosslinks. Treatment may result in elevated plasma levels of estradiol.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Estramustine (Emcyt) package insert[1]
- Estramustine (Emcyt) patient drug information (Chemocare)[3]
- Estramustine (Emcyt) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1981-12-24: Initial FDA approval
History of changes in EMA indication
- 1971-09-02: EURD
Also known as
- Generic name: estramustine phosphate sodium
- Brand names: Emcyt, Estracit, Estram, Estramin, X-Trant